LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Sold by Wakefield Asset Management LLLP

Wakefield Asset Management LLLP cut its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 22.2% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,091 shares of the medical instruments supplier's stock after selling 3,157 shares during the period. Wakefield Asset Management LLLP's holdings in LeMaitre Vascular were worth $931,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in LMAT. HighTower Advisors LLC raised its stake in shares of LeMaitre Vascular by 3.9% in the fourth quarter. HighTower Advisors LLC now owns 5,683 shares of the medical instruments supplier's stock valued at $524,000 after acquiring an additional 212 shares during the period. Swiss National Bank raised its position in LeMaitre Vascular by 0.8% in the 4th quarter. Swiss National Bank now owns 39,800 shares of the medical instruments supplier's stock worth $3,667,000 after purchasing an additional 300 shares during the period. Envestnet Portfolio Solutions Inc. raised its position in LeMaitre Vascular by 10.1% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 3,440 shares of the medical instruments supplier's stock worth $317,000 after purchasing an additional 315 shares during the period. Sei Investments Co. raised its position in LeMaitre Vascular by 9.6% in the 4th quarter. Sei Investments Co. now owns 96,857 shares of the medical instruments supplier's stock worth $8,924,000 after purchasing an additional 8,494 shares during the period. Finally, KLP Kapitalforvaltning AS purchased a new stake in LeMaitre Vascular in the 4th quarter worth about $811,000. 84.64% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Barrington Research reiterated a "market perform" rating on shares of LeMaitre Vascular in a research note on Tuesday, July 22nd. Five research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $97.83.

LeMaitre Vascular Stock Up 2.1%

Shares of NASDAQ:LMAT traded up $1.66 on Friday, reaching $82.43. The company had a trading volume of 116,150 shares, compared to its average volume of 109,785. The firm's 50 day simple moving average is $82.59 and its 200-day simple moving average is $87.34. LeMaitre Vascular, Inc. has a 52-week low of $71.42 and a 52-week high of $109.58. The company has a current ratio of 16.49, a quick ratio of 13.83 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $1.86 billion, a PE ratio of 41.63, a PEG ratio of 2.17 and a beta of 0.82.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.02). LeMaitre Vascular had a return on equity of 13.53% and a net margin of 19.96%. The firm had revenue of $59.87 million during the quarter, compared to analysts' expectations of $57.61 million. During the same period in the prior year, the firm posted $0.44 earnings per share. LeMaitre Vascular's revenue for the quarter was up 12.0% compared to the same quarter last year. As a group, analysts expect that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, May 29th. Shareholders of record on Thursday, May 15th were paid a dividend of $0.20 per share. The ex-dividend date was Thursday, May 15th. This represents a $0.80 annualized dividend and a yield of 0.97%. LeMaitre Vascular's payout ratio is presently 40.40%.

Insider Buying and Selling

In other news, CEO George W. Lemaitre sold 4,399 shares of the stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $85.10, for a total value of $374,354.90. Following the sale, the chief executive officer owned 1,827,003 shares in the company, valued at $155,477,955.30. This represents a 0.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 100,000 shares of company stock valued at $8,556,857 in the last 90 days. 9.50% of the stock is owned by corporate insiders.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.